Logo
x

Search

Subscribe Now

HER2

Daiichi Sankyo and AZ's Trastuzumab Deruxtecan Receives CHMP's Recommendation for Approval to Treat HER2 Positive Metastatic Breast Cancer

Daiichi Sankyo and AZ's Trastuzumab Deruxtecan Receives CHMP's Recommendation for Approval to Treat HER2 Positive Metastatic Breas...

  • December 14, 2020
Daiichi Reports EMA's Validation of MAA and Accelerated Assessment for Trastuzumab Deruxtecan to Treat HER2 Positive Metastatic Breast Cancer

Daiichi Reports EMA's Validation of MAA and Accelerated Assessment for Trastuzumab Deruxtecan to Treat HER2 Positive Metastatic Br...

  • July 7, 2020
Seattle Genetics Report Updated Results of Tukysa (tucatinib) in HER2CLIMB Study for Patients with HER2-Positive Breast Cancer with Stable or Active Brain Metastases #ASCO20

Seattle Genetics Report Updated Results of Tukysa (tucatinib) in HER2CLIMB Study for Patients with HER2-Positive Breast Cancer wit...

  • June 1, 2020
Pfizer to Launch Two Oncology Biosimilars at Lowest Wholesale Acquisition Cost in the US

Pfizer to Launch Two Oncology Biosimilars at Lowest Wholesale Acquisition Cost in the US

  • January 24, 2020
Celltrion and Teva Report Results Updated Results of CT-P6 in P-III Study for Patients Receiving Neoadjuvant Treatment for HER2-Positive Early Breast Cancer

Celltrion and Teva Report Results Updated Results of CT-P6 in P-III Study for Patients Receiving Neoadjuvant Treatment for HER2-Po...

  • August 21, 2019
Novartis Reports Results of Kisqali in Second Phase P-III MONALEESA-3 Study for HR+/HER2- Advanced Breast Cancer in Women

Novartis Reports Results of Kisqali in Second Phase P-III MONALEESA-3 Study for HR+/HER2- Advanced Breast Cancer in Women

  • August 1, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.